Bliss GVS Pharma
NSE: BLISSGVS · ISIN INE416D01022 · Healthcare
₹655.00+30.80 (+4.93%)
Monday 9 November, 13:16 IST. Delayed. Source: Yahoo Finance.
Price chart
₹655.00 +30.80 (+4.93%) today
The day
- Previous close
- ₹624.20
- Open
- ₹621.90
- Day high
- ₹655.40
- Day low
- ₹601.00
Listed on NSE since 26 July 2010.
Key numbers
- Market value
- ₹6,640.49 Cr
- P/E (trailing)
- 41.98
- EPS (trailing)
- ₹14.87
- Price to book
- 5.54
- Dividend yield
- 0.24%
- Debt to equity
- 0.02
- Profit margin
- 13.5%
- Beta
- 1.20
- Volume today
- 2.95 L
- Average volume
- 3.41 L
Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.
Revenue and profit
| Year | Revenue | Net profit |
|---|---|---|
| FY23 | ₹747.43 Cr | ₹70.86 Cr |
| FY24 | ₹765.91 Cr | ₹75.45 Cr |
| FY25 | ₹801.80 Cr | ₹84.30 Cr |
| FY26 | ₹920.64 Cr | ₹129.13 Cr |
Source: Yahoo Finance, from annual reports. Consolidated where reported.
Quarterly results
| Quarter | Revenue | Net profit | Profit vs year ago |
|---|---|---|---|
| Q2 FY27Jul–Sep 2026 | ₹313 Cr | ₹52 Cr | +91.7% |
| Q1 FY27Apr–Jun 2026 | ₹286 Cr | ₹50 Cr | +16.4% |
| Q4 FY26Jan–Mar 2026Audited | ₹257 Cr | ₹36 Cr | +128.9% |
| Q3 FY26Oct–Dec 2025 | ₹218 Cr | ₹23 Cr | – |
| Q2 FY26Jul–Sep 2025 | ₹244 Cr | ₹27 Cr | – |
| Q1 FY26Apr–Jun 2025 | ₹207 Cr | ₹43 Cr | – |
Source: Bliss GVS Pharma’s results filed with NSE, consolidated (the whole group). Net profit is the share of Bliss GVS Pharma’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.
Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.
Balance sheet
| As on | September 2026 | March 2026 |
|---|---|---|
| Fixed assets | ₹470 Cr | ₹457 Cr |
| Investments | ₹4 Cr | ₹5 Cr |
| Inventories | ₹188 Cr | ₹151 Cr |
| Owed by customers | ₹567 Cr | ₹517 Cr |
| Cash and equivalents | ₹37 Cr | ₹35 Cr |
| Total assets | ₹1,582 Cr | ₹1,492 Cr |
| Borrowings | ₹0 | ₹3 Cr |
| Total liabilities | ₹251 Cr | ₹261 Cr |
| Shareholders’ equity | ₹1,290 Cr | ₹1,193 Cr |
Source: Bliss GVS Pharma’s half-yearly statements of assets and liabilities filed with NSE, consolidated. Companies file these every September and March.
About Bliss GVS Pharma
Bliss GVS Pharma Limited engages in the development, manufacturing and marketing of pharmaceutical formulations in India and internationally. The company offers anti-diabetic, anti-infective, anti-inflammatory, antifungal, antihemorrhoidal, antimalarial, antiseptic, cardiovascular, dermatological, gastrointestinal, gynaecology, neoro/cns, ophthalmic, otc drugs, respiratory, urology, and supplementary drug products, as well as engages in pain management services. It exports its products. Bliss GVS Pharma Limited was incorporated in 1984 and is based in Mumbai, India.
- Industry
- Drug Manufacturers - Specialty & Generic
- Based in
- Mumbai
- Employees
- 1,033
Company website · Profile: Yahoo Finance
In the news
All newsNo headlines name Bliss GVS Pharma in the last day or two.
Dividends and corporate actions
All companies- Dividend - Re 1 Per Share
Dividend · ex-date 8 July 2026
- Interim Dividend - Re 0.50 Per Share
Dividend · ex-date 18 February 2026
- Annual General Meeting/Dividend - Rs 0.50 Per Share
Dividend · ex-date 24 July 2025
- Annual General Meeting/Dividend - Rs 0.50 Per Share
Dividend · ex-date 18 July 2024
- Annual General Meeting/Dividend - Re 0.50 Per Share
Dividend · ex-date 12 July 2023
- Annual General Meeting/ Dividend - Rs 0.50 Per Share
Dividend · ex-date 20 June 2022
- Annual General Meeting/Dividend - Rs 0.50 Per Share
Dividend · ex-date 13 September 2021
- Annual General Meeting/Dividend - Rs 0.50 Per Share
Dividend · ex-date 17 September 2020
Source: NSE. Latest first, 8 of 20.
Information only, not investment advice. Prices are delayed.